


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**APPROVAL OF “LIMAPROST TABLETS” FOR MARKETING**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “Limaprost Tablets” (利馬前列素片) (Kailitong (凱立通)), a drug developed by the Group for the improvement of micro-circulation and analgesia, has obtained drug registration certificate granted by the National Medical Products Administration of the PRC. Limaprost Tablet is the only small-molecule drug with a specific indication for the treatment of lumbar spinal stenosis in its package insert. It is the first drug in China to address the pathological mechanism of lumbar spinal stenosis and has the dual effect of improving neurological microcirculation and neurological function, which serves as the basic medication for the management of lumbar spinal stenosis.

Spinal stenosis is one of the most common diseases in the middle-aged and elderly population, with an estimated annual diagnosis of over 30 million patients in China (*Note*). Patients with lumbar spinal stenosis suffer from chronic and recurrent back and leg pain, numbness, weakness and intermittent claudication due to disturbance of blood circulation caused by pressure on the nerve tissues of the lumbar spine, which seriously affects the quality of life of patients and threatens their physical and mental health. Currently, there is no small-molecule drug approved for the specific indication of improving the symptoms of lumbar spinal stenosis in China, with significant clinical needs left unsatisfied.

As a synthetic derivative of prostaglandin E1, Limaprost has multiple pharmacological effects such as improving peripheral circulation disorders, increasing blood flow to nerve tissues, improving hyperalgesia and improving nerve function, and has good therapeutic effects on patients with lumbar spinal stenosis. The Group has overcome a number of technical difficulties in manufacturing prostaglandin-like substances into oral preparations through its self-developed high-end preparation platform, and has successfully applied for and received approval for marketing of the drug. The launch of Limaprost Tablets may practically address the pressing clinical needs of patients with lumbar spinal stenosis by providing them with a new solution, thereby helping them to walk freely and healthily as soon as possible.

*Note: Sources – Census data of the National Bureau of Statistics of China*

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 20 February 2023

*As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*